Fenofibrate in Ulcerative Colitis

Sex: All

Ages: 18 Years – 75 Years

Phase: PHASE2, PHASE3

Enrollment: 60

Sponsor: Tanta University

Summary

Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.

Eligibility Criteria

Inclusion Criteria:Age ≥ 18 yearsBoth males and females will be includedNegative pregnancy test and effective contraception.Mild and moderate UC patients diagnosed and confirmed by an endoscopeExclusion Criteria:BreastfeedingSignificant liver and kidney function abnormalitiesColorectal cancer patientsOther inflammatory bowel diseases (CD).Patients with severe UCPatients taking rectal or systemic steroidsPatients taking immunosuppressives or biological therapiesAddiction to alcohol and/or drugsKnown allergy to the Fenofibrate

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05753267). StuddyBuddy aggregates publicly available trial information.